Gluten-free food market: Trends and Growth (7.13% CAGR) Segments Forecast 2016-2020

About Post-Menopausal Vaginal Atrophy Drugs

Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.

Technavio’s analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.

The market is divided into the following segments based on geography:
• Americas
• EMEA
• APAC

Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Complete report details @ https://www.wiseguyreports.com/reports/417264/global-post-menopausal-vaginal-atrophy-drugs-market 

Key vendors
• Pfizer Inc.
• Allergan Inc.
• Shionogi & Co. Ltd.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.

Other prominent vendors
• Bayer
• Bionovo
• EndoCeutics
• Foamix Pharmaceuticals
• Ligand Pharmaceuticals
• Pantarhei Bioscience
• Pep-Tonic Medical
• TherapeuticsMD
• Upsher-Smith Laboratories

Market driver 
• Favorable healthcare reforms in the US
• For a full, detailed list, view our report

Market challenge
• Patent expiry of branded products
• For a full, detailed list, view our report

Market trend
• Paradigm shift to non-estrogenic therapies
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/417264/global-post-menopausal-vaginal-atrophy-drugs-market 

TABLE OF CONTENT

PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Key buying criteria
PART 05: Overview: Vaginal atrophy
• Symptoms
• Causes
• Pathophysiology
• Diagnosis
• Treatment
• Epidemiology
PART 06: Branded drug profiles
• Activella
• Enjuvia
• Estrace
• Femring
• Premarin
• Osphena
• Vagifem
PART 07: Market landscape
• Market overview
• Market size and forecast
PART 08: Market segmentation by drug class
• Topical estrogen
• Systemic estrogen
PART 09: Geographical segmentation
• Global PVA drugs market by geographical segmentation 2015-2020
• PVA drugs market in Americas
• PVA drugs market in US
• PVA drugs market in EMEA
• PVA drugs market in Europe
• PVA drugs market in APAC
• PVA drugs market in Japan
PART 10: Market drivers
• Significant unmet medical needs
• Favorable healthcare reforms in US
• Increase in awareness of PVA
• Cost-effective OTC drugs
PART 11: Impact of drivers
PART 12: Market challenges
• Patent expiry of branded products
• Low diagnosis rates
• Poor patient adherence
• Side effects of drugs
PART 13: Impact of drivers and challenges
PART 14: Market trends
• Paradigm shift to non-estrogenic therapies
• Increased R&D
• Patient assistance programs
• Strategic alliances
PART 15: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Pfizer
• Allergan
• Shionogi
• Novo Nordisk
• Teva Pharmaceutical
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
PART 17: Explore Technavio 

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=417264

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)